I am honored to welcome you to the 1st International Conference on Advances in Migraine Sciences (ICAMS), which will be held in Copenhagen, March 10-12, 2022. More than 1,100 people have already registered for ICAMS.
The scientific programme consists of state-of-the-art lectures, debates, and poster presentations on issues of interest for the migraine field.
ICAMS 2022 is a hybrid event that provides the possibility of online participation for international attendees; thus, aiming to meet the needs of all colleagues worldwide who are interested in migraine.
Conference participation is free of charge and reflects our commitment to free and timely knowledge sharing.
It should be emphasized that all ICAMS content will be available on demand to allow conference participants to access videos without the constraints of the time schedule.
Register today at: https://icams2022.com/
Dr. Messoud Ashina
The International Conference on Advances in Migraine Sciences held from March 10 to 12, 2022, aims to develop a research agenda and facilitate use of novel approaches to advance our understanding of disease mechanisms underlying migraine and ascertain best practices for clinical management
ICCN Clinical Report
From: Journal of Natural Products 2022
- Naturally occurring products frequently form the basis of drug therapies that are available today.
- In this study, CBD oil was found to block the capacity for Sars-CoV-2 to enter human cells, providing a mechanism for prevention and therapeusis
- To identify small molecule therapeutic agents, affinity selection-mass spectrometry was used to discover botanical ligands to Sars-CoV-2 spike protein
- Cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA) compounds found in CBD oil were found to prevent infection in human epithelial cells by SARS-CoV-2.
- Further testing shows that CBDA and CBGA had neutralizing effect on infected cells. SARS-CoV-2 variants B117 and B1351 were studied. Additional focus forming assays demonstrated effective blocking of virus infection by variants.
- Volunteers were tested with oral administration of .063mg/kg of CBDA equal to 5.71 mg for a 200lb person.
ABSTRACT: As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection−mass spectrometry was used for the discovery of botanical ligands to the SARS-CoV-2 spike protein. Cannabinoid acids from hemp (Cannabis sativa) were found to be allosteric as well as orthosteric ligands with micromolar affinity for the spike protein. In follow-up virus neutralization assays, cannabigerolic acid and cannabidiolic acid prevented infection of human epithelial cells by a pseudovirus expressing the SARS-CoV-2 spike protein and prevented entry of live SARS-CoV-2 into cells. Importantly, cannabigerolic acid and cannabidiolic acid were equally effective against the SARS-CoV-2 alpha variant B.1.1.7 and the beta variant B.1.351. Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2.
Richard B. van Breemen, Ruth N. Muchiri, Timothy A. Bates, Jules B. Weinstein, Hans C. Leier, Scotland Farley, and Fikadu G. Tafesse. Cannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants. J Nat Product – January 2022